Certainly, the recent approval of Tarlatamab, the first BiTE for solid tumors targeting DLL3, a protein found in small cell lung cancer and in pancreatic cancer, opens the possibility of future studies of this BiTE in PaCa. Here, DLL3 is linked to permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.